Yourgene Health PLC Yourgene launches Sage 32 plex (4319M)
January 08 2019 - 1:00AM
UK Regulatory
TIDMYGEN
RNS Number : 4319M
Yourgene Health PLC
08 January 2019
Yourgene Health plc
("Yourgene", the "Company")
Yourgene launches Sage(TM) 32 plex
High throughput NIPT solution for clinical laboratories
Manchester, UK - 8 January 2019: Yourgene Health (AIM: YGEN),
the international molecular diagnostics group which commercialises
genetic products and services, is pleased to announce the launch of
the Sage(TM) 32 plex test, a new high throughput non-invasive
prenatal testing ("NIPT") and analysis solution for clinical
laboratories.
Sage(TM) 32 plex uses the latest technology to detect placental
DNA in a maternal blood sample, enabling pregnant women to get
fast, safe and reliable test results, and reducing the number of
women needing to undergo invasive follow-up tests with associated
risks. The Sage(TM) 32 plex solution significantly improves
efficiency, enabling up to 32 samples to be processed in one
sequencing run, compared with just 12 samples previously. This will
provide laboratories with enhanced flexibility, scalability and
cost-effectiveness, while retaining all the high qualities of the
existing Sage(TM) prenatal screen test.
A combination of both workflow improvements and upgraded
analysis methods have been incorporated to improve the test's
overall performance and efficiency, with the addition of the new
Yourgene QS250 instrument into the workflow.
The higher throughput test runs on ThermoFisher's Ion Torrent
sequencing technology and will be available internationally.
Yourgene plans to launch a CE-IVD marked version of the library
preparation kit that is used in the Sage(TM) 32 plex workflow in
the coming months.
Yourgene provides two complementary screening solutions,
Sage(TM) and the IONA(R) test (CE-IVD), to meet the requirements of
laboratory customers, clinicians and pregnant women across
different international locations.
The Sage(TM) prenatal screen differs from the IONA(R) test in
that it offers screening on a wider range of clinical conditions,
including trisomy 21, trisomy 18 and trisomy 13, sex chromosome
aneuploidies and some clinically relevant microdeletions. The
analysis element is undertaken via a cloud-based bioinformatics and
software solution called Sage(TM) Link, which has been enhanced
with additional features and an improved user-friendly
interface.
Lyn Rees, CEO of Yourgene Health, commented: "This latest
product launch from Yourgene is an important enhancement of our
Sage(TM) solution. Many territories around the world - particularly
developing NIPT markets - need the scalability and
cost-efficiencies of a higher throughput NIPT solution that does
not compromise on quality. With Sage(TM) 32 plex, we are almost
trebling the throughput, making it a highly efficient solution for
our international laboratory network which we are very excited to
commercialise.
"I look forward to providing additional updates as we continue
to develop and extend our product portfolio."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Yourgene Health plc Tel: +44 (0)161
Lyn Rees, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@yourgene-health.com
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213
Liam Murray / James Caithie 0880
finnCap (Broker) Tel: +44 (0)20 7220
Geoff Nash / Matthew Radley (Corporate Finance) 0500
Tim Redfern (Corporate Broking)
Vigo Communications Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0238
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions.
Yourgene Health's first commercialised products are non-invasive
prenatal tests (NIPT) for Down's syndrome and other genetic
disorders, targeting a share of an emerging billion-dollar global
market.
Prenatal screening is an established clinical practice, but
accuracy challenges with traditional methods are driving the need
for NIPT and other DNA-based reproductive health testing solutions.
Yourgene Health's customer-focused products and services support
all types of customer, irrespective of size, geography and market
maturity. Our commercial footprint is already established in the
UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene
Health is aiming to extend its genetic testing offering into
complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore. For more information visit
www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAXFXELXNEFF
(END) Dow Jones Newswires
January 08, 2019 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024